NCT03826875.

Study name	Depression in haemorrhagic stroke
Methods	Study type: interventional (clinical trial) Estimated enrolment: 224 participants Allocation: randomised Intervention model: parallel assignment Intervention model description: double‐blinded placebo‐controlled randomised trial Masking: triple (participant, care provider, investigator) Primary purpose: prevention
Participants	Country: USA Setting: inpatient Inclusion criteria Age 18 to 85 years Subarachnoid haemorrhage from a ruptured cerebral aneurysm Consent Exclusion criteria Non‐English speaking Taking therapy for depression or related mental health diagnoses before admission Medical contraindications to fluoxetine therapy Pregnancy or considering getting pregnant during the trial period at the time of consent. Active psychosis Incarcerated or in police custody Comorbidity or a score > 26 on the MoCA
Interventions	Experimental: fluoxetine 20 mg/day for a period of 1 year Comparator: placebo 20 mg/day for a period of 1 year
Outcomes	Primary outcomes at 1 year Depression measured using HAM‐D Depression measured using PHQ‐9 Secondary outcomes at 1 year: Anxiety measured using Hamilton Rating Scale for Anxiety Fatigue measured using Fatigue Severity Scale Healthcare utilization measured using Self‐Report Health Service Utilization and Medication Use Social support measured using Multidimensional Scale of Perceived Social Support (MSPSS)
Starting date	1 March 2019
Contact information	Cory M Kelly: kellycm@neurosurgery.washington.edu
Notes	NCT03826875